Overview

* Becton Dickinson's ( BDX ) preliminary Q4 revenue grows 8.3% yr/yr but misses analyst expectations

* Full-year fiscal 2025 revenue rises 8.2% on a reported basis

* Company expects full-year adjusted EPS at or above midpoint of guidance

Outlook

* BD expects full-year fiscal 2025 adjusted EPS at or above midpoint of prior guidance

* BD aims to drive growth and margin momentum with strategic investments

Result Drivers

* SEGMENT GROWTH - Strong performance in BD Interventional, Advanced Patient Monitoring, and Medication Delivery Solutions contributed to revenue growth

* CHALLENGES IN PHARMA AND BIOSCIENCES - Greater than anticipated impact in Pharmaceutical Systems vaccines and Biosciences academic and government research affected results

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q4 Miss $5.89 $5.91

Revenue bln bln (12

Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 9 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Becton Dickinson and Co ( BDX ) is $205.50, about 8.3% above its October 14 closing price of $188.36

* The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 12 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)